Activation of multiple growth factor signalling pathways is frequent in meningiomas

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Meningiomas are primary brain tumors with limited treatment options beyond surgery and radiotherapy.
• Chemotherapeutic strategies for meningiomas are currently restricted.
• Understanding active molecular pathways is crucial for developing novel therapeutic approaches.

Purpose of the Study:

• To investigate the expression and activation of growth factor receptors, their ligands, and downstream signaling pathways in meningiomas.
• To correlate receptor expression with chromosome 22q loss.
• To identify potential new therapeutic targets for meningioma treatment.

Main Methods:

• Immunohistochemistry was used to analyze 30 meningioma samples.
• Expression of multiple growth factor receptors (VEGFR, PDGFRβ, Axl, EGFR, IGF receptor) and their ligands was assessed.
• Downstream signaling proteins (Mek, Erk, Jnk, Akt, pS6RP) and chromosome 22q loss were analyzed.
• Western blot was employed to confirm receptor expression.

Main Results:

• High expression of VEGFR, PDGFRβ, Axl, EGFR, and IGF receptor was observed in the majority of meningiomas.
• Expression of ligands and downstream signaling proteins was widespread across tumors.
• Membrane EGFR expression was significantly reduced in meningiomas with chromosome 22q loss.
• Axl receptor was widely expressed, and EGFR expression was selective in NF2-intact meningiomas.

Conclusions:

• Meningiomas commonly exhibit activation of multiple growth factor receptors and signaling pathways, regardless of tumor grade.
• The Axl receptor represents a promising novel therapeutic target for meningiomas.
• Anti-EGFR therapies may have limited efficacy in meningiomas associated with chromosome 22q loss.